AtaiBeckley (ATAI) stock is in focus as the company explores strategic options for psychedelic drug BPL-003, seeking a potential $2B+ deal. Read more here.
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, FDA alignment and a DSMB recommendation. Claim 70% Off TipRanks ...
GH Research's stock rallied after saying the FDA lifted a hold on its experimental depression treatment The FDA lifted its hold on GH Research's psychedelic drug, sending the company's shares soaring.
HELUS Pharma has rebranded and moved to Nasdaq, signaling a shift toward late-stage clinical development and commercial focus ...
In this article, we will be taking a look at the 7 Most Promising Psychedelic Stocks According to Hedge Funds. The psychedelic industry is poised to have a significant “second wave,” transforming from ...
WASHINGTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- With the United States in a pivotal election year, the Multidisciplinary Association for Psychedelic Studies (MAPS) released its Policy Guidebook, a ...
(The Center Square) - State leaders across the country are pushing for medical trials of the psychedelic drug ibogaine to treat neurological conditions. Former Texas Gov. Rick Perry spoke at the ...
Analysts consider AtaiBeckley’s MDMA candidate a “high-risk, high-reward” bet after the drug demonstrated reductions in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results